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823-3 Effect of Intravenous Glycoprotein llblllla Receptor 
Antagonists on Survival in Percutaneous Coronary 
Interventions: A Meta-Analysis 
Evangelia Kawouni, Demosthenes G. Katritsia John P. loannidis, Athens Euroclinic, 
Athens, Greece, University of loannina School of Medicine, loannina, Greece 
Background. Several randomized trials have shown that intravenous antagonists of the 
platelet glycoprotein llblllla receptor reduce the incidence of myocardial infarction (Ml), 
and composite cardiac outcomes (death, MI or revascularization) in patients undergoing 
percu:utaneous coronary intervention (PCI). However, individual studies have not had ade- 
quate power to examine differences in mortality. 
Methods: We performed a meta-analysis of 19 randomized placebo-controlled trials (20 
comparisons, n=20,137) of intravenous glycoprotein llblllla receptor antagonists in 
patients undergoing PCI. Death was the primary outcome. 
Results:Mortality was significantly reduced at 30 days (risk ratio [RR] 0.69 [95% Cl, 
0.53-0.90]), 6 months (RR 0.79 [95% Cl, 0.64-0.97]), and including longer follow-up (RR 
0.79 [95% Cl, 0.66-0.941) with no significant between-study heterogeneity. The relative 
risk reduction was largely similar in trials on patients with or without acute MI; in trials 
continuing or discontinuing heparin after the procedure; and in trials using stents or other 
PCI as the intended primary procedure. At 30 days and 6 months, Ml and composite out- 
comes were significantly reduced pcO.001 for all). Major bleeding was significantly 
increased only in trials where heparin infusion was continued afler the procedure (RR 
1.70 [95% Cl, 1.36-2.141). while there was no excess bleeding when heparin was discon- 
tinued (RR 1.02 [95% Cl, 0.65.1.241). 
Conclusion:ln patients undergoing PCI, glycoprotein Ilb/llla receptor antagonists confer 
a significant, and sustained decrease in the risk of death. 
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823-4 Prior Treatment With Statins Decreases Cardiac 
Biomarker Rise in Patients Undergoing Percutaneous 
Coronary Interventions 
Sean Halliqan, Joerg Hermann, Ryan Lennon, Geralyn Pumper, Stuart Higano, 
Verghese Mathew, David R. Holmes, Jr., Amir Lerman, Mayo Clinic-Rochester, 
Rochester, MN 
Background: Statins have been shown to reduce primary and secondary cardiac events 
in patients with coronary artery disease. However, it is unclear what the mechanism is for 
this benefit in patients undergoing precutaneous coronary intervention (PCI); we sought 
to determine if statins reduce the post-PC1 rise in cardiac biomarkers and postulated that 
this may be one mechanism for the observed benefit. 
Methods: We reviewed 1496 patents from the Mayo Clinic Interventional Registry who 
underwent PCI during the years 2000 and 2001. Patients with recent myocardial infarc- 
tion. shock, chronic renal disease or pre-procedural cardiac biomarker elevation were 
excluded. Patients were separated into two groups, Group 1 (n=752) consisted of 
patients on statins and Group 2 (n= 746) of patients not on statins prior to PCI. 
Results: Prior lo adjustment for baseline differences, Group 1 patients had a significantly 
lower rate of cardiac biomarker elevation post-PC1 compared to Group 2 patients (n= 200 
(27%) vs. n=236 (32%), p= 0.03). After adjusting for baseline differences, there were sig- 
nificantly fewer elevations in Troponin T levels (p=O.O49) and a trend towards fewer ele- 
vations of any cardiac enzymes (p=O.O56) post-procedure in Group 1. At follow up, 
unadjusted Kaplan-Meier curves indicate a significantly lower rate of death or myocardial 
infarction in Group 1 patients (p=O.O12). 
Conclusions: In this retrospective study, patients on statin therapy prior to PCI had a 
lower rise in cardiac biomarkers than those not on statin therapy. This maybe a mecha- 
nism for the cardiovascular benefits seen in patients on statins undergoing PCI. 
3:00 p.m. 
823-5 Clopidogrel Pretreatment Reduces Platelet 
Inflammatory Marker Expression in Patients 
Undergoing Percutaneous Coronary Intervention 
Frank J. Zidar, Martin J. Quinn, Deepak L. Bhatt, Deepak P. Vivekananthan, Herbert D. 
Aronow. Stephen G. Ellis, Edward Plow, Eric J. Top& The Cleveland Clinic Foundation. 
Cleveland, OH 
Background: Inflammation is thought to play an important role in the pathogenesis of 
complications after percutaneous coronary intervention (PCI). Pretreatment with the 
platelet ADP receptor antagonist clopidogrel reduces ischemic complications after PCI. 
We examined the effect of clopidogrel pretreatment (>24 hours) on platelet inflammatory 
marker expression after PCI. 
Methods: Patients undergoing elective PCI at the Cleveland Clinic were recruited into 
the study. Platelet and serum expression of the inflammatory markers CD40L and 
CD62P were compared in patients pretreated or not pretreated with clopidogrel. Blood 
was drawn before and after PCI. Platelet CD40L and CD62P expression in ADP (30pM) 
and TRAP (%M) activated samples were quantified by flow cytometry. Results are pre- 
sented as the geometric mean fluorescence intensity of the platelet population minus the 
fluoresence of isolypic control antibody. Soluble .CD40L levels were determined by 
ELISA. 
Results: Complete data was available on 71 patients. 30 (42%) were pretreated with clo- 
pidogrel for a median of 5 days. Mean age was 66+11 years, 75% were male. 
45A 
Preprocedure no pre-rx clap. pre 
CD40L (ADP) 2.72 1.74 
CD40L (TRAP) 5.18 4.06 
CD62P (ADP) 196.01 75.71 
CD62P (TRAP) 274.51 166.00 
soluble CD40L 1.21 1.06 
Postprocedure 
CD40L (ADP) 2.75 1.26 
CD40L (TRAP) 4.50 1.79 
CD62P (ADP) 141.17 57.71 
CD62P (TRAP) 208.64 135.17 
soluble CD40L 0.17 0.10 
-rx p value 
p = .I1 
p = .42 
p = .0003 
p = ,024 
p = .85 
p = .I4 
p = ,019 
p=.OcO2 
p=.O55 
p = ,028 
Conclusions: Clopidogrel pretreatment reduces platelet inflammatory marker expres- 
sion, specifically CD62P. prior to and immediately after PCI. Pretreatment may also 
decrease levels of soluble CD40 after PCI. In addition to the known anti-platelet activity 
of clopidogrel, these anti-inflammatory eflects may explain part of the clinical benefit of a 
clopidogrel pretreatment strategy. 
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823-6 Benefit of Clopidogrel in Patients Undergoing 
Percutaneous Coronary Intervention in the CURE Trial 
Receiving and Not Receiving an lntracoronary Stent 
Shamir R. Mehta, Madhu K. Natarajan, Thomas Wittlinger, Joao Morais. Matyas Keltai, 
Hans-Jurgen Rupprecht, Michel E. Bertrand, Keith A. Fox, Salim Yusuf. McMaster 
University, Hamilton, ON, Canada 
Background: It is well established that patients undergoing percutaneous coronary 
intervention (PCI) receiving a stent benefit from treatment with clopidogrel, in addition lo 
aspirin. In certain situations. it may not be possible to insert a stent. This analysis 
explores the consistency of benefit with clopidogrel in those patients treated with and 
without a stent. 
Methods: In the CURE trial, patients were randomized to receive clopidogrel 300 mg 
loading dose. followed by 75 mg a day for up to one year or matching placebo, in addition 
to aspwn. The 2,552 patients undergoing PCI in the trial were divided into 2 groups: 
those receiving a stent and those not receiving a stent. Outcome events, cardiovascular 
(CV) death or myocardial infarction (Ml), were analyzed in these groups lo determine if 
there was consistency of benefit with clopidogrel. 
Results: Overall, among the 2,552 patients undergoing PCI in the CURE study, there 
was a significant reduction In CV death or Ml with clopidogrel compared with placebo 
(relative risk reduction 31%, P=O.O02). 466 patients did not receive an intracoronary stem 
(253 placebo and 233 clopidogrel) and 2066 received at least one stem (1092 placebo 
and 1060 clopidogrel). Clopidogrel was beneficial both in those not receiving a stent 
(RRR 44%. P=O.O26) and in those receiving a stent (RRR 27%, P=O.O20) (Table). 
Conclusion: In patients with ACS undergoing PCI, clopidogrel is beneficial in those 
treated with a stem. and in those receiving balloon angioplasty alone. 
CV death or Ml from random,zanon to end (up ,o 1 year) 
Group Placebo Clopidogrel Relative Risk 95% Cl P value 
All patients 169/1345 (12.6%) 116/1313 (6.6%) 0.69 0.54-0.67 0.002 
No Stent 41/253 (16.2%) 221233 (9.4%) 0.56 0.34-0.95 0.026 
stent 126/1092 (11.7%) 94/1060 (6.7%) 0.73 0.56-0.95 0.020 
POSTER SESSION 
1127 Percutaneous Coronary Intervention and 
Outcomes 
Monday, March 31, 2003, 3:00 p.m.-!%00 p.m. 
McCormick Place, Hall A 
Presentation Hour: 3:00 p.m.-4:OO p.m. 
1127-187 The French Registry of Left Main Coronary Artery 
Treatment: Preliminary Results 
Marc Silvestri, Thieny Lefkre, Pierre Labrunie, Khalife Khalife, G. Bayet. Marie-Claude 
Morice M. Bedossa. A. Chmait, On behalf of the FLM Registry Investigators. UCV, -1 
Marseille, France, lnstitut Cardiovasculaire Paris Sud, Massy, France 
Background: CABG is the established treatment for unprotected left main coronary 
artery lesions (LMCA). However, PCI is now proposed as an alternative 
Methods:A prospective registry was set-up in 11 high-volume French centers during 13 
months to evaluate the outcome of pts with LMCA. 
